This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Background: The pharmacokinetics of IFNβ-1a in MS patients are poorly understood. We have previously reported an ELISA sensitive and specific for measuring serum IFNβ-1b levels in patients with MS.
Objective: We describe an ELISA to measure interferon β-1a (Avonex) in the serum of MS patients following IM administration.
Methods: We have developed an ELISA for detecting serum IFNβ-1a in MS patients receiving 6 million units (MU) of IFNβ-1a, IM once weekly. The specificity of this ELISA was confirmed by the lack of cross-reactivity with other cytokines except for IFNβ-1b.
Results: Serum IFNβ-1a levels were measured at 3 and 6 months after initiating treatment with IFNβ-1a in 10 MS patients. At 3 months, all 10 patients had detectable levels ranging from 68 to 86 IU/mL. At 6 months, IFNβ-1a could be detected in the serum of all but three patients, with levels ranging from 64 to 81 IU/mL. A kinetic study of IFNβ-1a serum levels in a separate group of six MS patients who had been receiving IFNβ-1a for several months was carried out. Blood was drawn before and 2, 4, 6, 8, and 24 hours after IFNβ-1a injection. Peak serum IFNβ-1a levels were observed at 8 hours and became undetectable at 24 hours after injection.
Conclusion: The described ELISA may have useful clinical applications in examining the correlation between serum IFNβ-1a levels and clinical efficacy.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Alert Me
Recommended articles
Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis
Neutralizing antibodies to interferon β-1a and interferon β-1b in MS patients are cross-reactive
Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration
Neutralizing antibodies reduce MxA protein induction in interferon- beta-1a-treated MS patients